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Abstract
Background—Little is known about how shared decision making (SDM) is being carried out 
between older men and their health care providers. Our study aimed to describe the use of SDM 
key elements and assess their associations with prostate-specific antigen (PSA) testing among 
older men.
Methods—We conducted descriptive and logistic regression modeling analyses using the 2005 
and 2010 National Health Interview Survey data.
Results—Age-specific prevalence of PSA testing was similar in 2005 and 2010. In 2010, 44.1% 
of men aged ≥70 years had PSA testing. Only 27.2% (95% confidence interval, 22.2–32.9) of 
them reported having discussions about both advantages and disadvantages of testing. Multiple 
regression analyses showed that PSA-based screening was positively associated with discussions 
of advantages only (P < .001) and with discussions of both advantages and disadvantages (P < .
001) compared with no discussion. Discussion of scientific uncertainties was not associated with 
PSA testing.
Conclusions—Efforts are needed to increase physicians’ awareness of and adherence to PSA-
based screening recommendations. Given that discussions of both advantages and disadvantages 
increased the uptake of PSA testing and discussion of scientific uncertainties has no effect, 
additional research about the nature, context, and extent of SDM and about patients’ knowledge, 
values, and preferences regarding PSA-based screening is warranted.
Keywords
Aged; Prostate Cancer; Prostate-specific Antigen; Screening; Shared Decision Making
Since its introduction to follow men diagnosed with prostate cancer in the mid-1980s, the 
prostate-specific antigen (PSA) test has been used to screen men for prostate cancer, causing 
a downward shift in stage to disease more confined to the organ at the time of diagnosis.1,2 
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However, the benefit of PSA-based screening for prostate cancer on mortality is 
uncertain.3,4 In 2008, the US Preventive Service Task Force (USPSTF) recommended 
against screening for prostate cancer among men ≥75 years old because the incremental 
benefits of treatment for screening-detected prostate cancer were negligible.5 In 2012, the 
USPSTF revised its recommendation for PSA-based screening, recommending against 
routine PSA screening among men of all ages.6 Although the American Cancer Society and 
the American Urological Association agree that men who have less than a 10-year life 
expectancy should not be screened, they also point out that decisions need to be 
individualized because some men older than 70 years might live for many more years.7,8 
Prior studies from 2010 and 2011 reported that PSA-based screening for prostate cancer is 
being performed in a substantial number of men aged 70 years and older, with rates peaking 
at ages 70 to 74 years.9–11
Because of the uncertain effectiveness of PSA-based screening for reducing prostate cancer 
mortality and the potential harms resulting from over-diagnosis and overtreatment, most 
prostate cancer screening guidelines recommend that before testing clinicians should have a 
balanced discussion with patients about 3 key elements: the advantages, disadvantages, and 
scientific uncertainties of the benefits associated with screening.7,8 The process of making a 
decision based on these discussions is commonly referred to as shared decision making 
(SDM), which is also recommended.7,8 Studies have shown that physician’s 
recommendations, patient’s demographics, and health-related factors including age, 
education, estimated life expectancy, and comorbidity are associated with prostate cancer 
screening among older men.10–13 To our knowledge, the role of each key element in SDM in 
influencing PSA testing has not been well studied, in part because this information has not 
been collected by national surveys.14–16 In 2010, questions about these 3 key elements of 
SDM were added to the cancer control supplement of the National Health Interview Survey 
(NHIS), which is supported by the Division of Cancer Control and Prevention at the Centers 
for Disease Control and Prevention and the National Cancer Institute.
The purposes of this study were 3-fold: first, to estimate the prevalence of discussions about 
the advantages, disadvantages, and the scientific uncertainties of PSA testing before 
ordering the tests; second, to determine the effect of these key elements of SDM on the 
uptake of PSA-based screening; and third, to assess the effect of the 2008 USPSTF prostate 
cancer screening recommendations on PSA-based testing in this older population.
Methods
Data Source
To estimate the prevalence of PSA testing among men ≥40 years old, we used nationally 
representative data from the 2005 and 2010 NHIS (http://www.cdc.gov/nchs/nhis.htm). The 
survey is an annual, in-person, cross-sectional household survey that monitors health trends 
among noninstitutionalized US civilians aged 18 years and older. The final response rates 
for the adult samples were 69.0% in 2005 and 60.8% in 2010. More information on NHIS 
has been described elsewhere.13 Data from the 2010 NHIS included 6220 men. Excluded 
were 298 men (4.0%) who had a history of or missing information on prostate cancer and 
808 (11.0%) who had a reason other than routine screening or missing information on PSA 
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testing. Similarly, the 2005 NHIS analysis included 7192 men after excluding 1298 (15.2%). 
The analysis of the effect of SDM elements on PSA-based screening was restricted to the 
1045 men aged 70 years and older in the 2010 NHIS who reported no history of prostate 
cancer. The reasons to include men aged 70 to 74 years old are (1) men in this age group 
have the highest screening rate for prostate cancer and (2) about one fourth of men who had 
a low life expectancy (at least a 48% risk of 5-year mortality as defined by Drazer et al10) in 
this age group underwent PSA screening.
Study Variables
In both the 2005 and 2010 surveys, men aged 40 years and older were asked several 
questions about prostate cancer and PSA testing, including whether they had ever had a PSA 
test and, if so, the time of their most recent test and the main reason for having the test. The 
primary outcome of this analysis was defined as receipt of a PSA test, which was a part of a 
routine examination within the 12 months preceding the survey, among men with no history 
of prostate cancer.
The primary factors of interest in the 2010 analysis were 3 SDM elements: whether men had 
discussions with their providers about the advantages, disadvantages, and experts’ 
disagreement about the benefits of PSA-based screening for prostate cancer (noted hereafter 
as scientific uncertainties) before ordering the PSA tests. For the descriptive and multiple 
regression analyses, we combined the first 2 items (advantages and disadvantages) to form a 
new variable with the following 4 mutually exclusive categories: discussion of advantages 
only, discussion of disadvantages only, discussion of both advantages and disadvantages, or 
no discussion.
We grouped age into 3 categories: 70 to 74 years, 75 to 79 years, and ≥80 years. Race and 
ethnicity were grouped into 4 mutually exclusive categories: non-Hispanic white, non-
Hispanic black, Hispanic, and non-Hispanic other. We designated marital status using 3 
categories: married or living with a partner, divorced/widowed/separated, and never married. 
We classified educational status as less than high school, high school graduate, and more 
than a high school diploma. We defined access to health care with the question of whether 
respondents had a usual source of care, excluding emergency department visits. We also 
included the following health-related characteristics, which might have an influence on 
prostate cancer screening: a family history of prostate cancer (whether a respondent’s father, 
brother, or son had previously been diagnosed with prostate cancer); number of the 
following comorbidities (none, 1, 2, or ≥3 diseases): hypertension, stroke, emphysema, 
diabetes, chronic bronchitis, failing kidneys, liver condition, and heart disease; and a 
diagnosis of cancer other than prostate cancer.
Statistical Analysis
We used SAS-callable SUDAAN 9.2 software (Research Triangle Institute, Research 
Triangle Park, NC) for the analyses to account for the stratified, multistage-cluster sampling 
design.17 We estimated the age-specific prevalence and corresponding 95% confidence 
interval (CI) of PSA testing by age group and survey year. We also estimated the prevalence 
of the discussion of advantages, disadvantages, and scientific uncertainties. We then 
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conducted bivariate analysis and multiple logistic regression to determine the unadjusted and 
adjusted associations between PSA testing and SDM and demographic and health-related 
characteristics. For the unadjusted and adjusted analyses, we used the mutually exclusive 4-
level variable describing discussions with the provider.
We presented the results from the multiple regression model as adjusted percentages or 
predicted margins.18 Predicted margins for each subgroup were calculated from the logistic 
regression model as the average of the predicted probabilities of PSA test use, assuming that 
all survey participants were in that subgroup. These adjusted percentages allow easy 
comparisons among categories within a covariate. We calculated the relative standard error 
(standard error/estimated percentage) × 100 for each estimated percentage. An estimated 
percentage is considered unstable if its relative standard error is >30% or if the sample size 
is <30; these values should be interpreted with caution. We used general linear contrasts to 
assess the difference between each estimate with a reference level within a variable.
Results
The overall prevalence of PSA screening of men aged 40 years and older was 26.3% in 2005 
and 27.5% in 2010. As shown in Figure 1, men aged 70 to 74 years had the highest 
prevalence of PSA testing (49.0%). The frequency of PSA screening in 2005 and 2010 were 
similar for each age group. We assessed the prevalence of PSA testing and SDM factors 
based on data from the 2010 NHIS. Among men aged 70 years and older, 44.1% (95% CI, 
40.5–47.8) reported having had a PSA test, 41.7% (95% CI, 38.0–45.5) reported having a 
discussion about the advantages, 20.1% (95% CI, 17.5–23.0) reported having a discussion 
about the disadvantages, and 15.1% (95% CI, 12.7–18.0) reported having a discussion about 
scientific uncertainties. Among men who underwent PSA testing, only 27.2% (95% CI. 
22.2–32.9) reported having discussions about both advantages and disadvantages (data not 
shown).
Findings from the unadjusted analysis (Table 1) showed that all variables examined were 
significantly associated with PSA testing except for family history of prostate cancer and 
comorbidity. The percentage of PSA testing was significantly lower among men aged ≥80 
years (37.0%; 95% CI, 31.4–43.0) than among men aged 70 to 74 years (49%; 95% CI, 
43.0–55.0). Discussions of advantages only and of both advantages and disadvantages were 
significantly more likely than no discussion to result in PSA testing.
Findings from the multiple logistic regression analysis (Table 2) revealed that after 
controlling for all other variables in the model, the prevalence of PSA testing was 
significantly higher among men who reported having had a discussion about advantages 
only (57.4%; 95% CI, 48.9–65.4) or about both advantages and disadvantages (55.9%; 95% 
CI, 46.9–64.6) compared with men reporting no discussion (34.3%; 95% CI, 29.2–39.9). 
Significantly higher prevalence of PSA testing was observed among men aged 70 to 74 
years compared with men aged ≥80, among college-educated men compared with men with 
less than a high school education, and among married men or those living with a partner 
compared with men who were divorced, separated, or widowed.
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Discussion
Our analysis reveals that a large proportion of men aged 70 and older are undergoing PSA-
based screening for prostate cancer. More than 70% of these men reported not having 
discussions about advantages and disadvantages. When conversations did occur, health care 
providers more often focused on the advantages than disadvantages of PSA testing. 
Infrequent discussion of disadvantages of PSA screening had been observed by several 
studies.14,16 Among these, Hall et al14 administered a national survey of physicians 
regarding prostate cancer screenings and found that more than two thirds of physicians who 
provided a prescreening discussion encouraged their patients to have the test; fewer than 2% 
discouraged testing. Hoffman and colleagues16 surveyed 240 men aged 40 years and older 
and found that health care providers more frequently emphasized the advantages of 
screening (71%) than the disadvantages (18%). It has been consistently reported that a 
physician’s advice is a major determinant in a man’s decision to have a PSA test.19–21 Lack 
of SDM in the physicians’ office may result in prostate cancer screening that could cause 
unnecessary physical, psychological, and financial harm to patients. Prostate cancer 
screening guidelines from major medical organizations such as the American Cancer Society 
and the American Urological Association recommend that patients be fully informed by 
health care providers about the advantages, disadvantages, and the scientific uncertainties 
associated with PSA testing and that patients’ preferences should be considered in screening 
decisions.7,8
In 2012, on the basis of new evidence about the benefits and harms of the PSA test, the 
USPSTF revised its 2008 recommendations on prostate cancer screening. The new statement 
does not recommend routine PSA-based screening for any men, regardless of age.6 The 
USPSTF understands that screening decisions may differ based on patient-specific 
characteristics and clinical situations and emphasizes that men and their health care 
providers should continue to discuss the advantages and disadvantages of PSA testing for 
prostate cancer screening and that they should make informed decisions about whether 
testing is right for them. Efforts are needed to enhance physicians’ knowledge of and 
adherence to these SDM recommendations before ordering a PSA test.
We found that discussions of both advantages and disadvantages were associated with a 
higher prevalence of PSA test use. Similar findings also was observed by Ross and 
coworkers22 in an analysis of 2000 NHIS data and by Tannor et al23 in a study of African 
American men. However, in both of these studies it was not clear whether physicians 
provided balanced information on the harms and benefits of prostate cancer testing and 
whether patients were fully engaged in the discussion. Besides varied levels of knowledge 
among health care providers about SDM and how to conduct it, misaligned financial 
incentives for physician practices might partially account for encouraging PSA testing; 
physicians with a laboratory on site are more likely to order a PSA test.24 Similarly, higher 
levels of PSA testing have been observed in Veterans Affairs hospitals with primary care 
incentives compared with institutions without incentives.25 Thus, the nature, context, and 
extent of physician-patient discussions of advantages and disadvantages of PSA screening 
must be studied further. In addition, our study revealed that a discussion about scientific 
uncertainties had no influence on PSA testing and that educational attainment and marital 
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status were associated with a higher prevalence of PSA testing, as seen in other 
studies.11,13,22 Therefore, it is important to assess knowledge of and perspectives on prostate 
cancer screening among patients and their family members and educate them on how to 
make decisions consistent with their values and clinical needs.
Our study is subject to several limitations. First, the NHIS data were self-reported and are 
thus subject to recall bias. Self-reported screening behaviors may have been overestimated 
as a result of social desirability.26,27 Second, responses to SDM questions were structured as 
yes/no, lacking detailed information to understand what was discussed and whether the 
discussions were appropriate. Third, we were not able to assess men’s knowledge, values, 
and preferences on prostate cancer screening to provide a more complete picture of SDM 
because this information was not collected by the survey. Last, given that the response rates 
ranged from 60% to 70%, our population-based estimates might be suboptimal. However, 
the calculations of weights, which were adjusted for differences in probability of selection 
and nonresponse, might have partially corrected the bias.
Conclusions
Our study suggests that the 2008 USPSTF recommendation had little effect on prostate 
cancer screening. A large number of older men have continued to undergo PSA testing, and 
more than 70% of these men reported not having discussions with their physician about 
advantages and disadvantages. Given the 2012 USPSTF recommendations that routine 
screening should not be performed in any age group of men, discussions between providers 
and men about the harms and benefits of prostate cancer screening is even more important. 
Discussions of advantages only and of both advantages and disadvantages of PSA testing 
seem to increase the uptake of prostate cancer screening. However, discussions of scientific 
uncertainties had no effect on PSA screening. Additional research is warranted to better 
understand the nature, context, and extent of physician-patient discussions and patients’ 
knowledge of, values, and preferences for prostate cancer screening. This will be critical to 
help men make decisions that are most consistent with their values and preferences.
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Figure 1. 
Age-specific prevalence and 95% confidence intervals of prostate-specific antigen screening 
within the past year, by year (2005 and 2010) of the National Health Interview Survey.
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Table 1
Unadjusted Associations Between Prostate-Specific Antigen Screening and Sociodemographic and Screening-
Related Factors Among Men Aged 70 Years or Older, National Health Interview Survey 2010
N* Percentage† 95% Confidence Interval P‡
Total 1045 44.1 40.5–47.8
Age, years .02
 70–74 396 49.0 43.0–55.0 Reference
 75–79 304 45.0 38.2–52.1 .400
 ≥80 345 37.0 31.4–43.0 .006
Race/ethnicity <.001
 Non-Hispanic white 727 47.0 42.9–51.1 Reference
 Non-Hispanic black 144 32.7 24.4–42.3 .004
 Non-Hispanic other 66 27.4 16.7–41.4 .011
 Hispanic 108 30.1 20.7–41.6 .003
Education <.001
 Less than high school 306 32.1 25.5–39.4 Reference
 High school graduate 308 40.1 34.2–46.3 .096
 Some college 202 47.3 39.7–54.9 .003
 College graduate 223 59.0 51.0–66.6 <.001
Marital status <0.001
 Married or living with partner 589 49.3 44.8–53.8 Reference
 Widowed, divorced, or separated 400 30.2 25.2–35.7 <.001
 Never married 55 39.8 27.1–54.2 .206
Usual source of medical care <.001
 Yes 998 45.5 41.8–49.3 Reference
 No 47 11.1 4.38–25.5§ <.001
Family history of prostate cancer .092
 Yes 78 53.7 42.4–64.6 Reference
 No 915 43.4 39.5–47.4 .091
Comorbidity .115
 None 229 37.8 30.9–45.2 Reference
 1 disease 336 47.0 41.1–52.9 .045
 2 diseases 278 42.4 35.6–49.4 .385
 ≥3 diseases 202 48.5 40.4–56.6 .049
Had any cancers excluding prostate cancer? .018
 Yes 182 52.9 44.8–60.9 Reference
 No 863 42.0 38.0–46.2 .018
Discussed scientific uncertainties <.001
 Yes 138 63.2 53.9–71.6 Reference
 No 874 40.8 36.9–44.8 <.001
Discussed advantages/disadvantages <.001
 None 606 31.4 26.9–36.3 Reference
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N* Percentage† 95% Confidence Interval P‡
 Advantages only 197 60.0 51.7–67.8 <.001
 Disadvantages only|| — — — —
 Both 185 62.6 54.6–70.0 <.001
*Number may differ from totals because of “don’t know,” refused, or missing responses.
†
Percentage of population estimates adjusted for National Health Interview Survey sampling design.
‡χ2 Test when the P value is located on a row of a main effect. P values for a general linear contrast comparing a row’s percentage to its reference 
level are located on the level (category) within the main effect.
§
Percentages should be interpreted with caution because the relative standard error is >30%.
||Count and unadjusted percentage are not shown because there are <30.
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Table 2
Adjusted Associations Between Prostate-Specific Antigen Screening and Sociodemographic and Screening-
Related Factors Among Men Aged 70 Years or Older, National Health Interview Survey 2010
Percentage* 95% Confidence Interval P†
Total 44.0 40.2–47.8
Age, years .086
 70–74 47.3 41.0–53.7 Reference
 75–79 45.5 38.8–52.4 .705
 ≥80 37.9 32.1–44.1 .036
Race/ethnicity .052
 Non-Hispanic white 45.6 41.3–49.9 Reference
 Non-Hispanic black 36.3 26.8–47.0 .910
 Non-Hispanic other 31.5 20.2–45.6 .562
 Hispanic 37.1 27.7–47.6 .098
Education .131
 Less than high school 38.8 31.5–46.7 Reference
 High school graduate 41.1 35.1–47.5 .650
 Some college 44.8 37.6–52.3 .255
 College graduate 51.1 42.9–59.2 .030
Marital status .001
 Married or living with partner 47.4 42.9–51.9 Reference
 Widowed, divorced, or separated 34.7 29.0–40.8 <.001
 Never married 36.5 22.9–52.7 .177
Usual source of medical care‡ .062
 Yes 44.4 40.6–48.3 Reference
 No 22.6 9.1–46.1 .025
Family history of prostate cancer .243
 Yes 49.8 39.5–60.0 Reference
 No 43.3 39.3–47.3 .245
Comorbidity .167
 None 38.9 32.0–46.4 Reference
 1 disease 46.8 41.3–52.5 .069
 2 diseases 41.1 34.0–48.6 .679
 ≥3 diseases 47.9 39.9–55.9 .095
Had any cancers excluding prostate cancer? .284
 Yes 47.8 39.6–56.1 Reference
 No 42.9 38.8–47.1 .285
Discussed scientific uncertainties .102
 Yes 51.8 40.9–62.6 Reference
 No 42.3 38.4–46.3 .106
Discussed advantages/disadvantages <.001
 None 34.3 29.2–39.9 Reference
J Am Board Fam Med. Author manuscript; available in PMC 2015 June 25.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Li et al. Page 13
Percentage* 95% Confidence Interval P†
 Advantages only 57.4 48.9–65.4 <.001
 Disadvantages only‡ 24.1 5.0–65.5 .545
 Both 55.9 46.9–64.6 <.001
*
Percentages of the population estimates were adjusted for the National Health Interview Survey sampling design.
†Wald χ2 test when the P value is located on a row of a main effect. P values for a general linear contrast comparing a row’s percentage to its 
reference level are located on the level (category) within the main effect using t test statistics.
‡
Percentages should be interpreted with caution because the relative standard error is >30%.
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